- Previous Close
0.0000 - Open
3.6400 - Bid 2.8100 x 40000
- Ask 3.2800 x 40000
- Day's Range
3.6400 - 3.6400 - 52 Week Range
2.2800 - 3.6400 - Volume
200 - Avg. Volume
16 - Market Cap (intraday)
281.787M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2300 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
www.inventivapharma.comRecent News: IVEVF
View More
Performance Overview: IVEVF
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVEVF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVEVF
View MoreValuation Measures
Market Cap
157.47M
Enterprise Value
203.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.79
Price/Book (mrq)
--
Enterprise Value/Revenue
12.04
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
14.72M
Net Income Avi to Common (ttm)
-184.21M
Diluted EPS (ttm)
-2.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--